Quantum BioPharma Lowers Debenture Conversion to C$3.00, Increases Warrants to 333.33 Units
Quantum BioPharma reduced its debenture conversion price to C$3.00 per share and cut warrant exercise price to C$3.75, while increasing the number of warrants per unit to 333.33. The company will complete a related debt settlement at the C$3.00 conversion price to lower outstanding obligations.
1. Debenture Terms Revision
Quantum BioPharma lowered the conversion price per debenture unit to C$3.00 per share and reduced the warrant exercise price to C$3.75, adjusting the financing structure after a decline in its subordinate voting share price. These amendments aim to make the debentures more attractive to investors under current market conditions.
2. Increased Warrant Allocation
Each debenture unit now includes 333.33 warrants, up from the originally announced allocation, offering greater equity upside potential if exercised. This increase enhances the value proposition for investors but raises the potential share count upon full exercise.
3. Debt Settlement Impact
The company will settle outstanding debt by converting at the lowered C$3.00 per share price, cutting cash outflows and reducing balance sheet liabilities. While this alleviates near-term liquidity pressures, it also increases the risk of future share dilution.
4. Strategic Financial Position
Quantum BioPharma retains a C$130 million tax loss carryforward and royalty rights until C$250 million in sales from its spun-out OTC product, providing potential future tax savings and revenue. It continues advancing its lead compound, Lucid-MS, targeting neurodegenerative and metabolic disorders in preclinical development.